Literature DB >> 25714546

The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy.

Jack Hutcheson1, Agnieszka K Witkiewicz1,2, Erik S Knudsen1,2.   

Abstract

The retinoblastoma tumor suppressor (RB) was the first identified tumor suppressor based on germline predisposition to the pediatric eye tumor. Since these early studies, it has become apparent that the functional inactivation of RB is a common event in nearly all human malignancy. A great deal of research has gone into understanding how the loss of RB promotes tumor etiology and progression. Since malignant tumors are characterized by aberrant cell division, much of this research has focused upon the ability of RB to regulate the cell cycle by repression of proliferation-related genes. However, it is progressively understood that RB is an important mediator of multiple functions. One area that is gaining progressive interest is the emerging role for RB in regulating diverse features of immune function. These findings suggest that RB is more than simply a regulator of cellular proliferation; it is at the crossroads of proliferation and the immune response. Here we review the data related to the functional roles of RB on the immune system, relevance to immune evasion, and potential significance to the response to immune-therapy.

Entities:  

Keywords:  RB; anti-viral immunity; differentiation; immune function; immunotherapy; transcription; tumor suppressor

Mesh:

Substances:

Year:  2015        PMID: 25714546      PMCID: PMC4825764          DOI: 10.1080/15384101.2015.1010922

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  72 in total

1.  Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein.

Authors:  B Krynska; J Gordon; J Otte; R Franks; R Knobler; A DeLuca; A Giordano; K Khalili
Journal:  J Cell Biochem       Date:  1997-11-01       Impact factor: 4.429

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression.

Authors:  H Zhang; A T Shepherd; D D Eason; S Wei; J I Diaz; J Y Djeu; G D Wu; G Blanck
Journal:  Cell Growth Differ       Date:  1999-07

Review 4.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 5.  Myeloid-derived suppressor cell heterogeneity in human cancers.

Authors:  Samantha Solito; Ilaria Marigo; Laura Pinton; Vera Damuzzo; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Ann N Y Acad Sci       Date:  2014-06       Impact factor: 5.691

6.  Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR.

Authors:  Smitha Pillai; Karoly Szekeres; Nicholas J Lawrence; Srikumar P Chellappan; George Blanck
Journal:  Gene       Date:  2012-10-03       Impact factor: 3.688

7.  Retinoblastoma protein regulation of surface CD74 (invariant chain) expression in breast carcinoma cells.

Authors:  Y Lu; G D Ussery; M Jacim; M Tschickardt; J M Boss; G Blanck
Journal:  Mol Immunol       Date:  1994-12       Impact factor: 4.407

8.  Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells.

Authors:  Y Lu; G D Ussery; M M Muncaster; B L Gallie; G Blanck
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

9.  A shared role for RBF1 and dCAP-D3 in the regulation of transcription with consequences for innate immunity.

Authors:  Michelle S Longworth; James A Walker; Endre Anderssen; Nam-Sung Moon; Andrew Gladden; Margarete M S Heck; Sridhar Ramaswamy; Nicholas J Dyson
Journal:  PLoS Genet       Date:  2012-04-05       Impact factor: 5.917

Review 10.  Beneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer.

Authors:  Tim Dalessandri; Jessica Strid
Journal:  Front Immunol       Date:  2014-07-22       Impact factor: 7.561

View more
  22 in total

Review 1.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

2.  Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer.

Authors:  Erik S Knudsen; Vishnu Kumarasamy; Sejin Chung; Amanda Ruiz; Paris Vail; Stephanie Tzetzo; Jin Wu; Ram Nambiar; Jared Sivinski; Shailender S Chauhan; Mukund Seshadri; Scott I Abrams; Jianmin Wang; Agnieszka K Witkiewicz
Journal:  Gut       Date:  2020-05-18       Impact factor: 23.059

Review 3.  Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.

Authors:  Christopher C Mills; E A Kolb; Valerie B Sampson
Journal:  Cancer Res       Date:  2017-11-02       Impact factor: 12.701

Review 4.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 5.  Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies.

Authors:  Susumu Kohno; Shunsuke Kitajima; Nobunari Sasaki; Chiaki Takahashi
Journal:  World J Stem Cells       Date:  2016-04-26       Impact factor: 5.326

6.  Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition.

Authors:  Andrea C Chaikovsky; Julien Sage
Journal:  Mol Cancer Res       Date:  2018-06-22       Impact factor: 5.852

7.  Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer.

Authors:  Jin-Ping Wang; Ji-Ping Yan; Jing Xu; Ting-Hui Yin; Rong-Qin Zheng; Wei Wang
Journal:  Cancer Manag Res       Date:  2019-07-16       Impact factor: 3.989

8.  Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations.

Authors:  Malte Simon; Sadaf S Mughal; Peter Horak; Sebastian Uhrig; Jonas Buchloh; Bogac Aybey; Albrecht Stenzinger; Hanno Glimm; Stefan Fröhling; Benedikt Brors; Charles D Imbusch
Journal:  J Transl Med       Date:  2021-05-12       Impact factor: 8.440

Review 9.  The Importance of Physiologically Relevant Cell Lines for Studying Virus-Host Interactions.

Authors:  David Hare; Susan Collins; Breanne Cuddington; Karen Mossman
Journal:  Viruses       Date:  2016-11-01       Impact factor: 5.048

10.  Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.

Authors:  W Song; Y Hwang; V M Youngblood; R S Cook; J M Balko; J Chen; D M Brantley-Sieders
Journal:  Oncogene       Date:  2017-06-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.